4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macular degeneration at the 2023 ARVO Annual MeetingOn track for completion of enrollment... | May 10, 2023